What neurological symptoms are linked to ivermectin overdose versus therapeutic doses?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Therapeutic ivermectin—typically 150–300 µg/kg (0.15–0.3 mg/kg) per dose—has a long safety record and usually does not cause central nervous system (CNS) problems because the drug is pumped out of the brain by the ABCB1/P‑glycoprotein transporter [1]. Overdose or misuse (large single doses, repeated high dosing, or veterinary formulations) is repeatedly linked in case series and reports to neurological signs such as ataxia, tremor, seizures, coma, visual disturbance/blindness, and altered consciousness [2] [3] [4].
1. How therapeutic doses usually behave — “designed to stay out of the brain”
Clinical guidance lists 150–300 µg/kg (with 200 µg/kg common for scabies) as standard therapeutic dosing; at these levels ivermectin is generally well tolerated because human ABCB1 (P‑glycoprotein) transports the drug out of the CNS, limiting brain exposure and major neurologic adverse events [1] [3]. Pharmacovigilance and large safety experience underpin the view that therapeutic doses rarely produce serious neurological toxicity in typical patients [1].
2. When neurologic reactions occur even at therapeutic doses — a genetic vulnerability
Case reports and pharmacovigilance series identify a clear exception: people with loss‑of‑function ABCB1 (ABCB1 nonsense mutations) can develop neurologic toxicity after otherwise normal therapeutic doses, including encephalopathy, confusion, and other CNS signs, because the protective brain efflux mechanism is impaired [1] [5]. Such human ABCB1 cases are rare but clinically important because they show therapeutic dosing is not universally safe [5] [1].
3. The overdose pattern — rapid-onset neurotoxicity after large doses
Multiple poison‑center and case‑series reports from COVID‑19–related misuse show that high single doses (often from veterinary products) produced neurologic symptoms within hours: confusion, ataxia, tremors, seizures, altered consciousness/coma, visual disturbances and sometimes death. US poison‑center reporting found rapid onset neurotoxicity after large single or repeated large doses, with most affected people older than 60 (median age 64) and many having taken veterinary formulations [6] [2].
4. Typical neurologic signs described in overdose case reports
Reported neurologic manifestations of ivermectin poisoning include central nervous system depression presenting as dizziness, somnolence or coma; motor dysfunction such as ataxia, increased tendon reflexes, tremors and muscle weakness; seizures; visual problems including mydriasis and blindness; and disorientation or confusion [4] [3] [7]. Case series also document gastrointestinal and systemic features alongside the neurologic picture [3] [2].
5. Evidence tying ivermectin to brain exposure in severe cases
Investigators have detected ivermectin in brain tissue in at least one fatal case and documented symptom recurrence on re‑exposure in others, supporting a causal link between high brain concentrations and neurologic injury rather than purely coincidental illness [8]. Experimental animal and forensic reports corroborate that very high systemic levels can overwhelm efflux mechanisms and allow CNS penetration [4] [9].
6. Patterns by formulation and duration — acute versus chronic toxicity
Reports distinguish two scenarios: acute toxicity from very large single or short high‑dose courses (often veterinary products) causing pronounced neurotoxicity, and milder chronic toxicity in people who took human‑label doses but for prolonged periods (weeks) — these chronic cases tended to have less severe but still notable neurologic symptoms [2].
7. Clinical course and management reported in the literature
Case reports show variable outcomes: many patients improve with supportive care and time, some required hospital monitoring for CNS depression, and rare fatal or severely disabling cases are described [4] [3]. There is no specific universally accepted antidote; treatments reported include supportive measures, activated charcoal for recent ingestion, and experimental approaches in animals [1] [9].
8. What the sources don’t say or resolve
Available sources do not provide population‑level rates comparing neurologic adverse events at therapeutic versus overdose exposures, nor do they define how common ABCB1 mutations are in affected patients in those series (not found in current reporting). Long‑term neurologic sequelae frequency after severe poisoning is described in isolated reports but not systematically quantified in the provided sources (not found in current reporting).
9. Bottom line for clinicians and the public
Therapeutic ivermectin doses are generally safe neurologically because ABCB1 keeps the drug out of the brain; however, overdose (especially veterinary formulations or exceptionally large doses) and rare genetic loss of ABCB1 function are linked to a reproducible toxidrome—ataxia, tremor, seizures, coma, visual loss, and altered mental status—which requires urgent medical assessment and supportive care [1] [2] [3].